PLoS ONE (Jan 2021)

Prevalence of metabolic syndrome and associated factors among patients with chronic Chagas disease.

  • Isis Gabrielli Gomes Xavier,
  • Marcelo Carvalho Vieira,
  • Luiz Fernando Rodrigues Junior,
  • Gilberto Marcelo Sperandio da Silva,
  • Paula Simplicio da Silva,
  • Marcelo Teixeira de Holanda,
  • Erica Rodrigues Maciel,
  • Fernanda Martins Carneiro,
  • Flavia Mazzoli-Rocha,
  • Luiz Henrique Conde Sangenis,
  • Fernanda de Souza Nogueira Sardinha Mendes,
  • Alejandro Marcel Hasslocher-Moreno,
  • Andrea Silvestre de Sousa,
  • Andrea Rodrigues da Costa,
  • Roberto Magalhães Saraiva,
  • Pedro Emmanuel Alvarenga Americano do Brasil,
  • Mauro Felippe Felix Mediano

DOI
https://doi.org/10.1371/journal.pone.0249116
Journal volume & issue
Vol. 16, no. 4
p. e0249116

Abstract

Read online

The increase in life expectancy and the migration of individuals with Chagas disease (ChD) from rural to urban centers exposes them to the development of chronic-degenerative abnormalities that may increase the prevalence of metabolic syndrome (MetS). The present study aimed to identify the prevalence of MetS and its components in individuals with chronic ChD. This is a cross-sectional study with 361 patients of both sexes, aging >18 years, followed at a national reference center (Rio de Janeiro, Brazil). MetS diagnosis followed the International Diabetes Federation 2005 criteria. The association between the variables was determined through logistic regression models. The mean age was and 60.7±10.8 years. About half (56.2%) were female and the majority self-reported their race as mulatto (59.8%). The percentage of individuals with MetS was 40.4%. The variables independently associated with MetS were age (OR 1.06; 95%CI 1.04-1.09), high education levels (OR 0.36; 95%CI 0.17-0.79) and cardiac form with heart failure (OR 0.34; 95%CI 0.17-0.68). Therefore, a high prevalence of MetS was found in this Brazilian chronic ChD cohort. The identification of the associated factors can facilitate the development of effective approaches for preventing and managing MetS in ChD patients.